Receptos, Inc., announced today that its selective sphingosine‐1‐ phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the and safety of in patients with moderately to severely active (UC).

Leading to the initiation of the RPC01-202 study, called , Receptos successfully filed an Investigational New Drug (IND) Application with the Division of Gastroenterology and Inborn Errors Products (DGIEP) of the Food and Drug Administration (USFDA). Receptos also has an active IND for RPC1063 with the Division of Neurology Products (DNP), under which an ongoing Phase 2/3 study for RPC1063 in Relapsing Multiple Sclerosis (RMS) is being enrolled.

TOUCHSTONE is a multi-national, multi-center, double-blind, randomized, placebo-controlled study investigating the effect of two active doses of RPC1063 versus placebo. The study is designed to enroll approximately 180 patients in North America, and Pacific. The primary objective of TOUCHSTONE is to compare the efficacy of RPC1063 for the induction of clinical in patients with moderately to severely active UC at eight weeks of treatment.

Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis
PR Newswire (press release)
“RPC1063 not only has the potential to demonstrate efficacy in both induction and maintenance therapy for ulcerative colitis, but could represent a first-in-class offering for S1P1R modulation as a of action to treat and more »

About Rob Hill

In 1994, Rob was a fit, healthy 23-year-old, an amateur runner and athlete. Until that time, he had never really been sick. He didn’t even have a regular doctor. When the illness started, it progressed rapidly. Daily diarrhea. Sustained stomach cramps. The diagnosis was Crohn’s disease, an inflammatory condition of the digestive tract. It got worse, and his weight plummeted from 185 to 105 pounds. After a year and a half, it became clear that his large intestine, his colon, needed to be removed. Rob decided he had to do something about it. The Seven Summits campaign, which we call “No Guts Know Glory” grew from Rob’s love of sport, adventure and the outdoors. By taking it to the extreme, and on a global basis, Rob hopes to show people everywhere that having these diseases or having an ostomy, like Rob does, shouldn’t stop you from leading a full life. You may not be able to climb mountains, but there are so many other things you can do. To further this goal, Rob started the Intestinal Disease Education and Awareness Society (IDEAS), from his home base in Vancouver, British Columbia.

Leave a Reply